drugset

drugset / Trial / NCT00285103

SPC2996 in Chronic Lymphocytic Leukaemia

NCT00285103 ↗

Phase 1/2 Completed 46 enrolled Santaris Pharma A/S

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether SPC2996 is effective and safe in the treatment of Chronic Lymphocytic Leukaemia (CLL)

Timeline

Start: 2005-06
Primary completion: —
Completion: 2007-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BECLANORSEN	Antisense oligonucleotide	—	—

Indications